AMD Clinical Trial - Quality-Assured Follow-up of Quiescent Neovascular

Status Recruiting

Clinical Trial Summary

This is a prospective, randomised, multi-site clinical trial testing the non-inferiority of community optometry follow-up of participants with QnAMD over 12 months

Clinical Trial Description

Neovascular Age-Related Macular Degeneration (nAMD) is a common vision threatening condition affecting mainly patients over the age of 65. At some point during follow-up the disease becomes inactive in many cases and does not need more injections. The risk of a flare-up is high, however, and patients need to continue to be seen every month for a significant period of time. Hospital-based eye clinics are struggling to cope with current and expected workload for assessing and treating patients with nAMD. Transferring care of these patients to the community closer to home would ease the workload for hospital based clinics and offer a better experience of care to patients. This study will recruit 742 patients with nAMD who have reached this inactive phase of the disease. Half of the patients that want to take part will continue to have their follow-up appointments in the hospital eye clinics as usual. The other half, chosen by chance, will have follow-up visits every month in a community optometrist practice by trained optometrists. The research team will provide the training for community optometrists. The study will seek to show that the community based care is no less safe than hospital-based care. The study will also check what is the impact of this different way of offering care on the NHS budget and how the patients and practitioners perceive this. The study will involve several hospital eye clinics across the country and several community optometrist practices. Meetings will also be held with patients to discuss their priorities and needs when looking at how to set up the community based eye clinics. During meetings with patients in preparation for this research, they felt positively about the possibility to receive care closer to home. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03893474
Study type	Interventional
Source	Moorfields Eye Hospital NHS Foundation Trust
Contact
Status	Recruiting
Phase	N/A
Start date	September 30, 2019
Completion date	November 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT01432847` - Cell Collection to Study Eye Diseases
Completed	`NCT00971464` - Low Vision Study Comparing EV Training vs. CCTV for AMD Rehabilitation	Phase 2
Terminated	`NCT00332657` - Anecortave Acetate Risk Reduction Trial (AART)	Phase 3
Recruiting	`NCT04796545` - Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration	N/A
Active, not recruiting	`NCT01766596` - Study the Signs of Ocular Degeneration in a Population Cohort (Dijon 3C Montrachet Cohort)	N/A
Completed	`NCT03322930` - Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)
Completed	`NCT01778491` - AMD Phenotype and Genotype Study
Completed	`NCT01016873` - INTREPID - IRay Plus Anti-VEGF Treatment For Patients With Wet AMD	Phase 2
Active, not recruiting	`NCT03845582` - Phase 3 Study of ALK-001 in Geographic Atrophy	Phase 3
Completed	`NCT03372746` - Generation of Induced Pluripotent Stem (iPS) Cell Lines From Skin Fibroblast Cells of Participants With Age-Related Macular Degeneration
Completed	`NCT03367767` - Age-Related Eye Disease Study 2 (AREDS2) 10-year Follow-On
Terminated	`NCT00333216` - Anecortave Acetate Risk-Reduction Trial (AART)	Phase 3
Completed	`NCT01570790` - Combretastatin A4 Phosphate in Patients With Neovascular Age-Related Macular Degeneration	Phase 1/Phase 2
Completed	`NCT00346866` - Anecortave Acetate Versus Placebo in AMD Patients Following PDT	Phase 2
Withdrawn	`NCT00726466` - Study of Efalizumab Combined With Intravitreal Ranibizumab in the Treatment of Age-Related Macular Degeneration	Phase 1
Completed	`NCT00306488` - OT-551 Antioxidant Eye Drops to Treat Geographic Atrophy in Age-Related Macular Degeneration	Phase 2
Terminated	`NCT02348359` - X-82 to Treat Age-related Macular Degeneration	Phase 2
Completed	`NCT01632527` - Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Age-Related Macular Degeneration (AMD)	Phase 1/Phase 2
Withdrawn	`NCT01339949` - Study to Evaluate the Safety and Effectiveness of IRay in Wet Age-related Macular Degeneration (AMD) Patients With Recurrent Leakage Secondary to Choroidal Neovascularisation (CNV)	N/A
Recruiting	`NCT03675880` - TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Quality-Assured Follow-up of Quiescent Neovascular Age -Related maculaR dEgeneration by Non-medical Practitioners — FENETRE

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms